The National Institute for Health and Clinical
Excellence (NICE) invited the manufacturer of rituximab
(RTX) [Roche] to submit evidence for the clinical and cost
effectiveness of RTX as first-line maintenance treatment for
patients with follicular non-Hodgkin’s lymphoma (fNHL)
whose disease has responded to induction therapy with RTX
plus cytotoxic chemotherapy (R-CTX) in accordance with the
Institute’s Single Technology Appraisal (STA) process.